AUDENTES THERAPEUTICS

AUDENTES THERAPEUTICS Overview

Company Headquarters: San Francisco, US

Founded: 2013

Workforce: ~500

Company Working: Audentes Therapeutics (Audentes) is a clinical-stage biotechnology company. The company is involved in developing adeno-associated virus-based (AAV) genetic medicines. Audentes is developing AT132, used for the treatment of X-linked myotubular myopathy; AT845, for the treatment of Pompe disease; AT342 to treat Crigler-Najjar syndrome; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia (CPVT), and is involved developing vector-based antisense treatments for the treatment of myotonic dystrophy.

Strategy

Audentes focused on commercializing and developing gene therapy products for patients living with rare life-threatening diseases such as Pompe disease, X-linked myotubular myopathy, Duchenne muscular dystrophy, and many more. The company has collaborated with Genethon for research & development, manufacture, and commercialization of products used for the treatment of such diseases.

Company Snapshot

$48.8M

Revenue

500

Employees

2013

Founded

San Francisco, US

Headquarters

SWOT Analysis

Strengths

Develops novel products
Competent management team

Weaknesses

Clinical-stage company

Opportunities

Focus on emerging economics
Growing demand for new therapies for rare diseases

Threats

Strict government rules and regulations have increased the cost of operations

Key Developments

Date	Approach	Development
December 2019	Definitive Agreement	Audentes Therapeutics and Astellas Pharma Inc. have entered into a definitive agreement for Astellas to acquire Audentes at a price of USD 60.00 per share in cash, representing a total equity value of approximately USD 3 billion.

Product Offering

AUDENTES THERAPEUTICS
- Pompe Disease Treatment

Financial Performance

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.